Paradigm Biopharmaceuticals (ASX:PAR) YoY EPS Growth: -123.26% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
12 GF Score
Price A$0.24
! 6 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals YoY EPS Growth?

Paradigm Biopharmaceuticals ASX:PAR -15.79% 12 YoY EPS Growth is -123.26% as of Jun. 2026. GuruFocus rates ASX:PAR with a GF Score™ of 12/100. The stock has 6 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Paradigm Biopharmaceuticals's YoY EPS Growth for the quarter that ended in Jun. 2026 was -123.26%.

Paradigm Biopharmaceuticals's Earnings per Share (Diluted) for the six months ended in Jun. 2026 was A$-0.10.

Paradigm Biopharmaceuticals YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals YoY EPS Growth Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.62 -9.82 -11.73 70.00 -153.33

Paradigm Biopharmaceuticals Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.38 89.57 -16.22 -229.41 -123.26
ASX:PAR
12GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Paradigm Biopharmaceuticals's YoY EPS Growth for the fiscal year that ended in Jun. 2026 is calculated as:

YoY EPS Growth (A: Jun. 2026 )
=(Earnings per Share (Diluted) (A: Jun. 2026 )-Earnings per Share (Diluted) (A: Jun. 2025 ))/ | Earnings per Share (Diluted) (A: Jun. 2025 ) |
=(-0.152--0.06)/ | -0.06 |
=-153.33 %

Paradigm Biopharmaceuticals's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.096--0.043)/ | -0.043 |
=-123.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -123.26% mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a YoY EPS Growth of -123.26% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Paradigm Biopharmaceuticals and its competitors.
Is Paradigm Biopharmaceuticals' YoY EPS Growth too high?
Paradigm Biopharmaceuticals' current YoY EPS Growth is -123.26%. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' YoY EPS Growth compare to VRTX and REGN?
Paradigm Biopharmaceuticals' YoY EPS Growth of -123.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current YoY EPS Growth is -123.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current YoY EPS Growth of -123.26%. The current YoY EPS Growth is -123.26%. Paradigm Biopharmaceuticals' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current YoY EPS Growth is -123.26% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
12GF Score

Get the complete analysis for ASX:PAR

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.24
Price